#Pharma
Total 5 articles
Semaglutide's patent expired in China on March 20. Now at least 10 Chinese rivals are queuing for approval, some claiming better efficacy. A $14B market is up for grabs.
Barclays dramatically cuts Novo Nordisk's CagriSema revenue projections from $25.4B to $4.4B, sending shockwaves through pharma investment community and raising questions about obesity drug market reality.
Merck (MSD) announced a revenue target of $70 billion by the mid-2030s, driven by new growth opportunities and a diversified pipeline to offset Keytruda's patent expiration.
PRISM by Liabooks
Place your ad in this space
[email protected]
China enters 'Biotech Innovation 2.0', focusing on commercialization to challenge US market dominance despite growing trade restrictions.
The FDA has approved a once-daily pill version of Novo Nordisk's blockbuster weight-loss drug Wegovy, offering a new option versus the weekly shot and escalating competition with Eli Lilly.
